Leritrelvir
- Generic Name
- Leritrelvir
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗轻中度新型冠状病毒感染（COVID-19）的成年患者。
- Associated Conditions
- -
- Associated Therapies
- -
Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06169085
- Locations
- 🇨🇳
Wuhan Jinyintan Hospital, Wuhan, China
Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06160622
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06031454
- Locations
- 🇨🇳
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath